CAMBRIDGE, Mass. and
BOULDER, Colo., Oct. 1, 2021 /PRNewswire/ -- Cogent
Biosciences, Inc. (Nasdaq: COGT), a biotechnology company
focused on developing precision therapies for genetically defined
diseases, today announced that the Company will present preclinical
data on bezuclastinib at the AACR-NCI-EORTC Virtual International
Conference on Molecular Targets and Cancer Therapeutics held
October 7-10, 2021.
Poster Presentation Details for Bezuclastinib:
Title: Preclinical data identifies bezuclastinib as a
differentiated KIT inhibitor with unique selectivity to KIT D816V
and minimal evidence of brain penetration
Virtual Poster Number: P257
Date/Time: All poster presentations are made available
by the conference at the opening of the meeting on October 7, 2021, at 9:00
am ET.
The presentation will be available on October 7, 2021 shortly after 9:00 am ET on the Cogent Biosciences website at
https://investors.cogentbio.com/events.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on
developing precision therapies for genetically defined diseases.
The most advanced clinical program, bezuclastinib, is a selective
tyrosine kinase inhibitor that is designed to potently inhibit the
KIT D816V mutation as well as other mutations in KIT exon 17. KIT
D816V is responsible for driving systemic mastocytosis, a serious
disease caused by unchecked proliferation of mast cells. Exon 17
mutations are also found in patients with advanced gastrointestinal
stromal tumors (GIST), a type of cancer with strong dependence on
oncogenic KIT signaling. In addition to bezuclastinib, the newly
formed Cogent Research team is developing a portfolio of novel
targeted therapies to help patients fighting serious, genetically
driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more
information at www.cogentbio.com. Follow Cogent Biosciences on
social media: Twitter and LinkedIn. Information that may be
important to investors will be routinely posted on our website and
Twitter.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-preclinical-data-on-bezuclastinib-at-aacr-nci-eortc-conference-301389367.html
SOURCE Cogent Biosciences, Inc.